Mainz Biomed CEO Guido Baechler Receives 440,000-Share Award

What Happened

• Guido Baechler, CEO of Mainz Biomed N.V. (MYNZ), received a grant of 440,000 restricted ordinary shares on February 13, 2026. The shares were issued at $0.00 (no cash consideration); reported value on the Form 4 is $0 since this is an award/grant, not an open-market purchase or sale.

Key Details

• Transaction date and type: 2026-02-13 — Award/Grant of 440,000 restricted shares (transaction code A).
• Price: $0.00 per share (grant); no cash paid.
• Pre-grant holdings (per footnote): 6,362 ordinary shares and 158,696 employee stock options were previously reported on a Form 3 filed Jan 26, 2026. The Form 4 notes the 440,000-share award in addition to those holdings.
• Footnotes: F1 — grant under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; F2 — prior holdings and options previously disclosed.
• Filing: Form 4 filed with accession 0001213900-26-018497 on 2026-02-19 reporting the Feb 13 transaction.

Context

• This was a compensation/retention award of restricted shares, not a market purchase or sale; such grants are commonly used for executive pay and retention and do not necessarily indicate buying or selling sentiment. No option exercise or immediate sale was reported in this filing.